|
Free
Zepbound's 80% revenue jump signals upside, but access and supply cap the bull case.
|
Free
Examining layoffs, Game Pass missteps, regulatory threats, and the $627B commercial backlog.
|
Free
Structural peptide demand favors Lilly, but peer data falls short of valuation proof.
|
Free
Cloud gross margins slide to 66% while capital expenditure reaches 30% of revenue in a capital-intensive transformation.
|
Free
Strong beat and raised guidance meet rich multiples and heavy reinvestment cash drag.
|
Free
Examining 570+ vulnerabilities, zero-days, and systemic failures that eroded trust in identity and authentication.
|
Free
Analyzing Microsoft's cloud, identity, and product lifecycle through the lens of cryptographic principles and systemic fragility.
|
Free
Oral GLP-1 and global filings signal a platform shift beyond injectable franchises.